What does this mean for patients? An FDA Fast Track designation DOES NOT mean that the drug has been approved for use by patients. AOC 1020 is still a long… Read More »
FDA Fast Track Designation for Avidity’s FSHD therapeutic
(Cautious) optimism in FSHD drug development
Patients are critical in helping to transform optimism into reality by Ken Kahtava, Chief Business Officer, FSHD Society Breakthroughs in FSHD research have identified the primary mechanism that causes FSHD…. Read More »
Stay warm and safe
Our monthly Wellness Hour invited Dr. Mark Tarnopolsky of McMaster University to discuss an issue that many with FSHD face in winter: feeling especially susceptible to cold temperatures. He explains… Read More »
Teaching future doctors about FSHD
If we want to control the narrative, we need to tell our stories by Brian Jude Loiacono I was formally diagnosed with FSHD in January 2019. At that time I… Read More »
Promising findings from Avidity’s myotonic dystrophy trial
A major breakthrough for the field of RNA therapeutics Avidity Biosciences announced today that its investigational treatment for myotonic dystrophy type 1 (DM1), called AOC 1001, can be delivered into… Read More »